BioRem Price To Sales Ratio vs Capex To Depreciation Analysis

BRM Stock

CAD 3.00 0.02 0.67%

BioRem financial indicator trend analysis is way more than just evaluating BioRem Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioRem Inc is a good investment. Please check the relationship between BioRem Price To Sales Ratio and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioRem Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Price To Sales Ratio vs Capex To Depreciation

Price To Sales Ratio vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioRem Inc Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have almost no relationship.

The correlation between BioRem's Price To Sales Ratio and Capex To Depreciation is 0.19. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of BioRem Inc, assuming nothing else is changed. The correlation between historical values of BioRem's Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of BioRem Inc are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., BioRem's Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.19

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing BioRem Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BioRem sales, a figure that is much harder to manipulate than other BioRem Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from BioRem's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioRem Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioRem Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, BioRem's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to climb to about 640.2 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop 3.18 in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	24.5M	28.9M	25.2M	18.5M
Depreciation And Amortization	343.6K	350.6K	382.7K	281.4K

Total Revenue Depreciation And Amortization

BioRem fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Current Deferred Revenue	Good Will	Intangible Assets	Non Currrent Assets Other
Total Assets		-0.06	0.67	0.67	0.77	0.58	-0.5	0.52	0.7	0.87	0.7	0.85	0.48	0.18	0.51	0.26	-0.49	0.61	0.99	-0.47	0.06	0.74	0.67	-0.23	-0.59	0.85
Short Long Term Debt Total	-0.06		0.26	0.55	-0.63	0.38	0.76	0.14	-0.36	0.01	-0.36	0.07	-0.42	0.81	0.04	0.28	0.25	0.7	-0.08	0.54	-0.7	0.35	0.23	-0.17	-0.02	0.05
Other Current Liab	0.67	0.26		0.56	0.33	0.52	-0.18	0.67	0.46	0.75	0.46	0.53	-0.01	0.58	0.29	-0.03	-0.41	0.64	0.61	-0.35	-0.44	0.46	0.35	-0.02	-0.04	0.67
Total Current Liabilities	0.67	0.55	0.56		0.08	0.54	0.18	0.22	0.13	0.49	0.13	0.77	0.17	0.57	0.34	0.38	-0.08	0.95	0.69	0.18	-0.25	0.91	0.67	-0.17	-0.56	0.44
Total Stockholder Equity	0.77	-0.63	0.33	0.08		0.25	-0.87	0.35	0.82	0.69	0.82	0.5	0.63	-0.39	0.37	0.06	-0.52	-0.03	0.76	-0.65	0.47	0.24	0.33	-0.13	-0.44	0.68
Property Plant And Equipment Net	0.58	0.38	0.52	0.54	0.25		0.09	0.64	0.29	0.64	0.27	0.43	-0.11	0.59	0.42	0.74	-0.17	0.6	0.51	-0.14	-0.36	0.52	0.82	-0.75	-0.25	0.72
Net Debt	-0.5	0.76	-0.18	0.18	-0.87	0.09		-0.05	-0.86	-0.45	-0.86	-0.15	-0.67	0.56	-0.37	0.27	0.39	0.3	-0.5	0.59	-0.63	0.1	0.03	-0.26	0.28	-0.35
Retained Earnings	0.52	0.14	0.67	0.22	0.35	0.64	-0.05		0.27	0.62	0.25	0.44	-0.14	0.47	0.09	0.22	-0.68	0.38	0.45	-0.57	-0.64	0.32	0.47	-0.53	0.21	0.77
Cash	0.7	-0.36	0.46	0.13	0.82	0.29	-0.86	0.27		0.69	1.0	0.26	0.66	-0.2	0.59	-0.03	-0.43	0.08	0.67	-0.47	0.38	0.13	0.26	0.04	-0.46	0.64
Non Current Assets Total	0.87	0.01	0.75	0.49	0.69	0.64	-0.45	0.62	0.69		0.69	0.58	0.25	0.34	0.55	0.22	-0.35	0.51	0.79	-0.46	-0.09	0.51	0.47	-0.2	-0.32	0.91
Cash And Short Term Investments	0.7	-0.36	0.46	0.13	0.82	0.27	-0.86	0.25	1.0	0.69		0.26	0.66	-0.21	0.58	-0.06	-0.42	0.08	0.67	-0.47	0.38	0.13	0.23	0.08	-0.46	0.62
Net Receivables	0.85	0.07	0.53	0.77	0.5	0.43	-0.15	0.44	0.26	0.58	0.26		0.34	0.23	0.18	0.24	-0.44	0.71	0.88	-0.32	-0.09	0.89	0.69	-0.24	-0.52	0.61
Common Stock Shares Outstanding	0.48	-0.42	-0.01	0.17	0.63	-0.11	-0.67	-0.14	0.66	0.25	0.66	0.34		-0.55	0.2	-0.14	-0.38	-0.02	0.53	-0.09	0.61	0.22	0.18	0.15	-0.67	0.27
Non Current Liabilities Total	0.18	0.81	0.58	0.57	-0.39	0.59	0.56	0.47	-0.2	0.34	-0.21	0.23	-0.55		0.22	0.26	0.1	0.76	0.12	0.07	-0.8	0.48	0.35	-0.24	0.2	0.3
Inventory	0.51	0.04	0.29	0.34	0.37	0.42	-0.37	0.09	0.59	0.55	0.58	0.18	0.2	0.22		0.27	-0.06	0.35	0.48	-0.27	0.17	0.38	0.41	-0.1	-0.43	0.45
Other Current Assets	0.26	0.28	-0.03	0.38	0.06	0.74	0.27	0.22	-0.03	0.22	-0.06	0.24	-0.14	0.26	0.27		0.12	0.33	0.24	0.18	-0.1	0.39	0.7	-0.81	-0.41	0.37
Other Stockholder Equity	-0.49	0.25	-0.41	-0.08	-0.52	-0.17	0.39	-0.68	-0.43	-0.35	-0.42	-0.44	-0.38	0.1	-0.06	0.12		-0.12	-0.5	0.6	0.23	-0.2	-0.34	0.21	0.02	-0.54
Total Liab	0.61	0.7	0.64	0.95	-0.03	0.6	0.3	0.38	0.08	0.51	0.08	0.71	-0.02	0.76	0.35	0.33	-0.12		0.61	0.08	-0.49	0.86	0.64	-0.2	-0.38	0.48
Total Current Assets	0.99	-0.08	0.61	0.69	0.76	0.51	-0.5	0.45	0.67	0.79	0.67	0.88	0.53	0.12	0.48	0.24	-0.5	0.61		-0.44	0.1	0.77	0.67	-0.19	-0.64	0.77
Short Term Debt	-0.47	0.54	-0.35	0.18	-0.65	-0.14	0.59	-0.57	-0.47	-0.46	-0.47	-0.32	-0.09	0.07	-0.27	0.18	0.6	0.08	-0.44		0.0	-0.09	-0.19	0.11	-0.18	-0.48
Common Stock	0.06	-0.7	-0.44	-0.25	0.47	-0.36	-0.63	-0.64	0.38	-0.09	0.38	-0.09	0.61	-0.8	0.17	-0.1	0.23	-0.49	0.1	0.0		-0.18	-0.15	0.27	-0.5	-0.19
Accounts Payable	0.74	0.35	0.46	0.91	0.24	0.52	0.1	0.32	0.13	0.51	0.13	0.89	0.22	0.48	0.38	0.39	-0.2	0.86	0.77	-0.09	-0.18		0.75	-0.31	-0.56	0.53
Current Deferred Revenue	0.67	0.23	0.35	0.67	0.33	0.82	0.03	0.47	0.26	0.47	0.23	0.69	0.18	0.35	0.41	0.7	-0.34	0.64	0.67	-0.19	-0.15	0.75		-0.73	-0.54	0.64
Good Will	-0.23	-0.17	-0.02	-0.17	-0.13	-0.75	-0.26	-0.53	0.04	-0.2	0.08	-0.24	0.15	-0.24	-0.1	-0.81	0.21	-0.2	-0.19	0.11	0.27	-0.31	-0.73		0.15	-0.49
Intangible Assets	-0.59	-0.02	-0.04	-0.56	-0.44	-0.25	0.28	0.21	-0.46	-0.32	-0.46	-0.52	-0.67	0.2	-0.43	-0.41	0.02	-0.38	-0.64	-0.18	-0.5	-0.56	-0.54	0.15		-0.37
Non Currrent Assets Other	0.85	0.05	0.67	0.44	0.68	0.72	-0.35	0.77	0.64	0.91	0.62	0.61	0.27	0.3	0.45	0.37	-0.54	0.48	0.77	-0.48	-0.19	0.53	0.64	-0.49	-0.37

Click cells to compare fundamentals

BioRem Account Relationship Matchups

BioRem fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	17.6M	22.0M	19.2M	20.7M	24.1M	15.1M
Other Current Liab	1.9M	3.3M	3.4M	4.2M	2.7M	2.0M
Total Current Liabilities	5.9M	7.8M	13.2M	12.9M	13.9M	7.9M
Total Stockholder Equity	11.7M	13.5M	2.0M	4.5M	6.7M	6.0M
Property Plant And Equipment Net	372.9K	1.4M	1.1M	1.0M	2.0M	2.1M
Net Debt	(6.4M)	(8.0M)	1.2M	971.1K	1.9M	2.0M
Retained Earnings	(9.1M)	(7.0M)	(5.7M)	(4.1M)	(1.9M)	(2.0M)
Cash	6.5M	8.9M	4.5M	3.8M	2.3M	3.1M
Non Current Assets Total	3.1M	3.7M	3.0M	3.0M	3.5M	1.9M
Cash And Short Term Investments	6.5M	8.9M	4.5M	3.8M	2.3M	2.7M
Net Receivables	5.7M	7.6M	10.1M	12.2M	15.1M	7.8M
Common Stock Shares Outstanding	38.7M	39.5M	37.4M	17.6M	17.1M	22.9M
Liabilities And Stockholders Equity	17.6M	22.0M	19.2M	20.7M	24.1M	15.1M
Inventory	1.3M	944.8K	901.7K	888.0K	901.1K	764.8K
Other Current Assets	1.0M	857.3K	658.9K	870.6K	2.3M	2.4M
Other Stockholder Equity	2.2M	2.2M	2.2M	2.3M	2.4M	2.3M
Total Liab	5.9M	8.4M	17.2M	16.2M	17.4M	9.0M
Total Current Assets	14.5M	18.3M	16.2M	17.8M	20.6M	12.4M
Accounts Payable	2.4M	1.8M	5.1M	4.7M	6.1M	3.4M
Accumulated Other Comprehensive Income	1.4M	1.1M	597.3K	1.4M	1.3M	653.8K
Current Deferred Revenue	1.6M	2.5M	3.0M	2.6M	4.3M	4.5M
Net Tangible Assets	12.9M	11.7M	13.5M	2.0M	2.3M	2.1M
Property Plant Equipment	262.5K	372.9K	1.4M	1.1M	1.3M	1.4M
Net Invested Capital	11.7M	13.5M	7.0M	8.8M	9.7M	8.1M
Net Working Capital	8.6M	10.5M	2.9M	4.9M	6.7M	5.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for BioRem Stock Analysis

When running BioRem's price analysis, check to measure BioRem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRem is operating at the current time. Most of BioRem's value examination focuses on studying past and present price action to predict the probability of BioRem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRem's price. Additionally, you may evaluate how the addition of BioRem to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC